Gene · 54890
Papers4,144
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 4,144
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanistic insights into the role of RNA demethylase ALKBH5 in malignant tumor therapy. | J Transl Med | 2025 | 40804394 | PubTator, text mining | PubMed |
| Temporal and spatial profiling of ALKBH5 activity through NAIL-MS and compartmentalized RNA isolation. | RNA | 2025 | 40796272 | PubTator, text mining | PubMed |
| DDX54 drives ALKBH5-mediated demethylation of selected transcripts to suppress interferon antiviral response. | J Virol | 2025 | 40793791 | Swiss-Prot, curated | PubMed |
| Unraveling the dual role of METTL3-mediated m6A RNA modification in bladder cancer: mechanisms, therapeutic vulnerabilities, and clinical implications. | Cancer Biol Ther | 2025 | 40778544 | PubTator, text mining | PubMed |
| Mechanisms and therapeutic strategies linking mesenchymal stem cells senescence to osteoporosis. | Front Endocrinol (Lausanne) | 2025 | 40761817 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| Epitranscriptomic alterations induced by environmental toxins: implications for RNA modifications and disease. | Genes Environ | 2025 | 40760453 | PubTator, text mining | PubMed |
| FTO-mediated the destabilization of RASGRF1 mRNA impedes thyroid cancer progression and suppresses macrophage M2 polarization. | Cell Biol Toxicol | 2025 | 40760370 | PubTator, text mining | PubMed |
| Epigenetic regulation of cancer stemness. | Signal Transduct Target Ther | 2025 | 40744921 | PubTator, text mining | PubMed |
| Comprehensive Analysis of N6-Methyladenosine (m6A) RNA Methylation Regulators in Soft Tissue Leiomyosarcoma. | Lab Invest | 2025 | 40744224 | PubTator, text mining | PubMed |
| M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges. | Front Oncol | 2025 | 40740874 | PubTator, text mining | PubMed |
| Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. | Signal Transduct Target Ther | 2025 | 40739089 | PubTator, text mining | PubMed |
| Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials. | Front Psychiatry | 2025 | 40735218 | PubTator, text mining | PubMed |
| RNA m6A modification: a key regulator in normal and malignant processes. | Cell Investig | 2025 | 40734692 | PubTator, text mining | PubMed |
| FTO-mediated MMP1 m6A modification promotes osteogenic differentiation of bone marrow mesenchymal stem cells via the ERK pathway in congenital scoliosis. | Sci Rep | 2025 | 40731128 | PubTator, text mining | PubMed |
| NSUN5 accelerates the progression of liver hepatocellular carcinoma by m5C-EFNA3-mediated glycolysis. | BMC Cancer | 2025 | 40730949 | PubTator, text mining | PubMed |
| Peptide Drug: Design and Clinical Applications. | MedComm (2020) | 2025 | 40717901 | PubTator, text mining | PubMed |
| The dual-edged sword: AlkB homolog 5-mediated autophagy regulation in cancers - molecular mechanisms and therapeutic implications: A review. | Int J Biol Macromol | 2025 | 40701469 | PubTator, text mining | PubMed |
| Unlocking the potential: m6A-RNA methylation in severe epidermolysis bullosa simplex. | Biosci Rep | 2025 | 40700032 | PubTator, text mining | PubMed |
| The 6-methyladenine erasers ALKBH5 and FTO influence chemotherapy efficiency in bladder cancer cell lines. | Ann Transl Med | 2025 | 40689068 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/papers?page=14